Carbohydrate key to C. diff vaccine

German researchers have synthesized a carbohydrate on the surface of an extremely virulent strain of Clostridium difficile, a potentially deadly hospital-acquired infection, that could lead to a vaccine for the difficult-to-treat disease. Max Planck Institute scientists hope that they can develop a vaccine based on the carbohydrate that enables the body to recognize and respond to the threat of infection. Article

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

To eradicate SARS-CoV-2, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA official says.

The U.K. government, fearing losing the supply race, agreed to buy 60 million doses of GSK-Sanofi's COVID-19 vaccine even before phase 1.